Anavex Life Sciences Corp. investors who purchased securities between November 26, 2025, and August 28, 2026, have until November 30, 2026, to ask the court to appoint them lead plaintiff in a proposed securities class action. Rosen Law Firm said the lawsuit alleges that Anavex lacked adequate internal controls and understated potential regulatory challenges arising from alleged misconduct by former Chief Executive Officer Christopher Missling. The complaint claims the company and other defendants made materially false or misleading statements, or omitted material information, about Anavex's business, operations and prospects during the proposed class period. No class has been certified.